Friday 6 November 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.

Revenue: +11.9%
EPS: −39.2%
Free cash flow: −52.1%

Quarter to September 2026, against a year earlier

547.62 5.12 +0.94%

Follow VRTX

Alert me

Market cap: $137.5B
P/E: 34.6×
Fwd P/E: 33.2×
Dividend yield: —
F-score: 8/9
Altman Z: 12.06
Beneish M: −2.17
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Vertex Pharmaceuticals Incorporated (VRTX) revenue by segment, product and region

	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023	Q4 FY2022	Q3 FY2022	Q2 FY2022	Q1 FY2022
TRIKAFTA/KAFTRIO	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other CF product revenues	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
CASGEVY	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
ALYFTREK	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other revenues	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Orkambi	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Kalydeco	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Symdeko/Symkevi	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Incivek	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Product revenues, net	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Vertex Pharmaceuticals Incorporated (VRTX) revenue by segment, product and region

Stockrow Weekly